Intellia Therapeutics, Inc. Aktie News

Shares of Intellia Therapeutics (NTLA -0.29%), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set by Wall Street analysts, there's still plenty of upside left for the stock.

CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

Cathie Wood is having a good year. The Ark Invest founder, CEO, and ace stock picker isn't back to her peak 2020 form when many of her exchange-traded funds (ETFs) more than doubled in value.

CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy...

News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling Buy, driven by strong progress in its late-stage gene editing therapies for HAE and ATTR-CM. NTLA's lead candidate, lonvo-z, has completed Phase 3 enrollment for HAE, offering a one-time infusion ad...

CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it has completed enrollment in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) for the treatment of hereditary angioedema (HAE). Topline data are expected i...

Tom Yeung here with your Sunday Digest .  Almost every multimillionaire investor I know has their version of “The One” – a single investment that built much of their wealth.

Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase her bet -- at a great price.